• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Roberta Herman, MD, to Become Joslin Diabetes Center President and CEO


Prior to her appointment, she served as executive director of the Group Insurance Commission (GIC), and as a Joslin trustee.

Career Growth

Roberta Herman, MD, has been selected as the Joslin Diabetes Center's new president and chief executive officer effective January 9, 2020, the Center’s board of trustees announced. Herman replaces Peter Amenta, MD, PhD, who announced this past fall that he would be stepping down at the end of 2019, after 10 years with Joslin. 

"Roberta's professional experience with both clinical and executive leadership positions at varied healthcare organizations makes her the ideal candidate to lead Joslin," says Ann Lagasse, chair of Joslin's Board of Trustees. "As a compassionate internist, Roberta's focus has always been on quality care, accessibility, and patient experience. She has worked on both the provider and payer side of healthcare, and understands the deep human and financial challenges of the diabetes epidemic. As Joslin continues to grow to address the prevalence of diabetes both nationally and globally, the Board looks forward to Roberta's commitment to lead our researchers, clinicians, educators, and staff so that we may continue to improve the lives of people with diabetes while supporting prevention and researching toward a cure."

Related: This Component is Key to Diabetes Self-Management

Herman comes to Joslin after nearly four years as executive director of the Group Insurance Commission (GIC), which provides and administers health insurance and other benefits to more than 450,000 employees and retirees of the Commonwealth, and their dependents. While there, Dr. Herman oversaw successful efforts to revamp the offerings of the GIC, created multiple new capabilities and efficiencies to improve interactions with GIC stakeholders, and presented a strategic plan to optimize and grow the quasi-independent state agency.

"It has been my privilege to work with Dr. Roberta Herman for years, most recently during her service to the Commonwealth in her capacity as executive director of the Group Insurance Commission," says Governor Charlie Baker. "Dr. Herman is an asset to the healthcare industry and brings with her to Joslin a wealth of knowledge and experience that I am confident will prove invaluable in the fight against diabetes."  

Previous to her service at GIC, Herman was the chief medical officer and then chief operating officer for Harvard Pilgrim Health Care, one of New England's largest non-profit managed healthcare organizations. Before that, she had been chief of internal medicine at Harvard Community Health Plan's Cambridge Center.

Prior to being selected as president and CEO, Herman served as a trustee of Joslin Diabetes Center for six years. She has been a clinical instructor at Harvard Medical School with hospital appointments at Mount Auburn Hospital and Beth Israel Deaconess Medical Center and a guest lecturer at the Harvard School of Public Health. She also has been a faculty mentor in Brigham and Women's Internal Medicine Residency.

"My career has frequently been focused on addressing population health challenges, and I am honored to serve as the next president and CEO of this storied institution singularly devoted to addressing one of the most pressing national and international public health challenges of our time," Herman says. "Since Dr. Joslin treated his first patient in Boston, people with diabetes have looked to Joslin for the latest in research discoveries, treatments, and most importantly hope for the future. I am excited to be joining the extraordinary Joslin team and look forward to supporting Joslin's very important mission."

Eliot Lurier, CPA, Joslin's CFO/COO, will serve as interim president and CEO in the short time prior to Herman's start date.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.